<DOC>
	<DOC>NCT01630018</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of belotecan or topotecan in patients with recurrent or refractory ovarian cancer (AOC).</brief_summary>
	<brief_title>Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial</brief_title>
	<detailed_description>A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan (CamtoBell inj.) or Topotecan in Patients with Recurrent or Refractory Ovarian Cancer</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Belotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>At least 18 years of age Histological or cytological diagnosis of AOC Stable disease (SD) or progression at time of study entry Recurrent or progressive AOC ≥ 90 days of duration of response for firstline therapy Measurable disease defined by RECIST criteria ECOG Performance Status of 0, 1, or 2 Life expectancy &gt; 3 months Adequate bone marrow, Renal, Hepatic reserve: absolute neutrophil (segmented and bands) count (ANC) ≥ 1500 cells/μL platelet count ≥ 100,000 cells/μL hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 X ULN Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0 X ULN Alkaline Phosphatase (ALP) ≤ 2.0 X ULN Serum creatinine &lt; 1.5mg/dL or calculated creatinine clearance &gt; 60mL/min Signed a written informed consent Active infection Symptomatic brain lesion Any other type of cancer during the previous 5 years except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix Severe concurrent diseases Prior anticancer therapy within 4 weeks before enroll Active pregnancy test and Pregnant or nursing women Participation in any investigational drug study within 28 days prior to study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Epithelial Ovarian Cancer</keyword>
	<keyword>Belotecan</keyword>
	<keyword>Topotecan</keyword>
</DOC>